Streetbeat News

Price Targets

MYGN

Wells Fargo has initiated coverage on Myriad Genetics with an Overweight rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:12 pm

EXAS

Wells Fargo has initiated coverage on Exact Sciences with an Overweight rating and set a price target of $75.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:11 pm

AVTR

Wells Fargo has initiated coverage on Avantor (NYSE:AVTR) with an Overweight rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:08 pm

BRKR

Wells Fargo has initiated coverage on Bruker with an Overweight rating and set a price target of $78.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:05 pm

RGEN

Wells Fargo has initiated coverage on Repligen with an Overweight rating and set a price target of $180.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:03 pm

MRVI

Wells Fargo has initiated coverage on Maravai LifeSciences with an Overweight rating and set a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:01 pm

MLAB

Wells Fargo has initiated coverage on Mesa Laboratories with an Underweight rating and set a price target of $120.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 9:59 pm

CDNA

Wells Fargo has initiated coverage on CareDx with an Underweight rating and set a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 9:54 pm

BIO

Wells Fargo has initiated coverage on Bio-Rad Laboratories with an Equal-Weight rating and set a price target of $340.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 9:52 pm

WGS

Wells Fargo has initiated coverage on GeneDx Holdings with an Equal-Weight rating and set a price target of $34.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 9:50 pm